Cancer in Portugal

IARC estimates 69,439 new cancer cases and 33,590 cancer deaths in Portugal in 2024; the commonest new cancers are colorectum, breast and prostate. This page is assembled automatically from OnCo's data: 316 trials with a site there, 5 institutions, 1 company, 5 people and 2 programmes and laws, and says what OnCo does not yet hold.

Cancer figures, GLOBOCAN 2024

Compare countries →

New cases

69,439

all cancers

Deaths

33,590

all cancers

Incidence rate

293.2

per 100,000, age-standardised

Mortality rate

106.3

per 100,000, age-standardised

Cumulative risk

28.2%

of a cancer by age 74

Population

10,425,297

IARC, 2024

Most new cases

Site	New cases	Rate	OnCo page
Colorectum	10,732	39.1	Colorectal cancer
Breast	9,100	88.5	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Prostate	7,677	62.6	Prostate cancer
Trachea, bronchus and lung	6,148	24.4	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Stomach	3,930	14.6	Gastric & gastro-oesophageal junction cancer
Bladder	3,602	11.5	Bladder & urothelial cancer
Non-Hodgkin lymphoma	2,834	13.1	Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma
Pancreas	2,191	7.2	Pancreatic ductal adenocarcinoma
Kidney	1,583	7.4	Renal cell carcinoma
Liver and intrahepatic bile ducts	1,541	5.8	Hepatocellular carcinoma

Most deaths

Site	Deaths	Rate	OnCo page
Trachea, bronchus and lung	5,589	19.8	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Colorectum	4,811	13.2	Colorectal cancer
Stomach	2,720	8.4	Gastric & gastro-oesophageal junction cancer
Breast	2,101	13.3	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Prostate	2,101	10.3	Prostate cancer
Pancreas	2,051	6.2	Pancreatic ductal adenocarcinoma
Liver and intrahepatic bile ducts	1,483	5.1	Hepatocellular carcinoma
Bladder	1,173	2.8	Bladder & urothelial cancer
Leukaemia	1,096	3.5	Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia
Non-Hodgkin lymphoma	1,027	3.1	Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma

Incidence: method 3a, national mortality estimates applied to model-based mortality-to-incidence ratios (country-specific registry data).
Mortality: method 1, trends in national rates projected to 2024.
Rates are age-standardised per 100,000 (World standard population), both sexes, all ages. Non-melanoma skin cancer is left out of the site lists, as on the deep dives. IARC lists the country as “Portugal”, in Southern Europe (Europe), Very High HDI, high income.
Source: Ervik M, Laversanne M, Lam F, Colombet M, Ferlay J, Filho AM, Bray F (2026). Global Cancer Observatory: Cancer Today (2024 estimates, version 1.0). Lyon, France: International Agency for Research on Cancer. https://gco.iarc.who.int/today, read through the IARC API on 2026-11-04.

Trials with a site here

316 trials in OnCo · 97 recruiting overall

316 trials

Trial			Lead sponsor
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis NCT04910685	Phase 2/3	Recruiting	Blueprint Medicines Corporation	88	2026-10-07
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer NCT06119581	Phase 3	Recruiting	Eli Lilly and Company	416	2026-10-07
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer NCT07525206	Phase 3	Recruiting	AbbVie	85	2026-10-07
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutati NCT07195695	Phase 3	Recruiting	Boehringer Ingelheim	202	2026-10-07
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pemb NCT03486873	Phase 3	Recruiting	Merck Sharp & Dohme LLC	782	2026-10-07
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer NCT05827081	Phase 3	Recruiting	Novartis Pharmaceuticals	229	2026-10-07
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML NCT07007312	Phase 3	Recruiting	Kura Oncology, Inc.	122	2026-10-07
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer NCT06890598	Phase 3	Recruiting	Eli Lilly and Company	366	2026-10-07
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) NCT06966700	Phase 3	Recruiting	Merck Sharp & Dohme LLC	326	2026-10-06
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Particip NCT06793215	Phase 3	Recruiting	Hoffmann-La Roche	288	2026-10-06
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) NCT06136650	Phase 3	Recruiting	Merck Sharp & Dohme LLC	330	2026-10-06
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) NCT06312176	Phase 3	Recruiting	Merck Sharp & Dohme LLC	259	2026-10-06
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Pl NCT06824467	Phase 3	Recruiting	Merck Sharp & Dohme LLC	197	2026-10-06
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL NCT04924075	Phase 2	Recruiting	Merck Sharp & Dohme LLC	84	2026-10-06
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive NCT07413939	Phase 2/3	Recruiting	Hoffmann-La Roche	206	2026-10-06
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) NCT06393374	Phase 3	Recruiting	Merck Sharp & Dohme LLC	314	2026-10-06
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma NCT06697301	Phase 2/3	Recruiting	Eikon Therapeutics	127	2026-10-06
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer NCT07155187	Phase 2/3	Recruiting	AbbVie	117	2026-10-05
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer NCT07005102	Phase 2/3	Recruiting	AbbVie	65	2026-10-05
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer NCT06982521	Phase 3	Recruiting	Relay Therapeutics, Inc.	243	2026-10-05
TeliMET NSCLC-01 NCT04928846	Phase 3	Recruiting	AbbVie	317	2026-10-05
FORTIFI-HN01 NCT06788990	Phase 2/3	Recruiting	Bicara Therapeutics	231	2026-10-02
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor NCT06472245	Phase 3	Recruiting	OSE Immunotherapeutics	207	2026-10-02
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relaps NCT07589634	Phase 2	Recruiting	Janssen Research & Development, LLC	38	2026-10-01
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer NCT06369285	Phase 2	Recruiting	Puma Biotechnology, Inc.	53	2026-10-01
Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma NCT05287945	Phase 1/2	Recruiting	Oncorena AB	10	2026-10-01
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Re NCT05519085	Phase 3	Recruiting	Celgene	266	2026-09-30
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and P NCT07361510	Phase 3	Recruiting	Bristol-Myers Squibb	284	2026-09-30
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC NCT06765109	Phase 3	Recruiting	Nuvalent Inc.	159	2026-09-30
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment NCT07472517	Phase 3	Recruiting	Boehringer Ingelheim	245	2026-09-29

(showing the first 30)

Trial records in OnCo whose ClinicalTrials.gov entry lists at least one site in Portugal, captured 2026-10-07 to 2026-10-07. Recruiting first, then the most recently updated. The status is the study's overall status; whether a site in Portugal is open is on the registry page, under Contacts and Locations.

Institutions, companies and people

5 institutions

Champalimaud Foundation, Champalimaud Clinical Centre ECHoS: Cancer Mission Hubs network (EU Cancer Mission)Instituto Português de Oncologia de Coimbra Francisco Gentil Instituto Português de Oncologia de Lisboa Francisco Gentil Instituto Português de Oncologia do Porto Francisco Gentil

1 company

Mondego Bio

5 people

People whose main affiliation in OnCo is an institution or company in Portugal.

Carla Gonçalo Júlio Oliveira Leonor Beleza Maria Margarida Torres de Ornelas Teresa Cotta-Dias

Screening, vaccination and law

Term

Breast cancer screening programme in Portugal

Portugal runs a national breast cancer screening programme started in 1990, offering mammography or breast tomosynthesis, as recorded by IARC's CanScreen5 survey (2016).

Term

Portugal: Law 75/2021 and the right to be forgotten in credit and insurance

Since 1 January 2022 Portuguese law stops banks and insurers from collecting health information about a serious illness, cancer included, once ten years have passed since the end of treatment, or five years if the illness occurred before age 21, when someone applies for a mortgage, consumer credit or the insurance tied to it.

Approvals

Portugal is an EU member state, so an EU centralised authorisation covers it: 309 products in OnCo carry a sourced EU row that is approved or conditional. See the approvals by region matrix. National procedures and reimbursement are not recorded.

From the country research ranking

Research funders: FCT; Liga Portuguesa Contra o Cancro.
Named in the ranking: IPO Porto and Lisbon.

From the country ranking's hand-curated row; follow its source before relying on a figure.

What OnCo does not yet hold

No registry figures. The figures above are IARC's estimates; OnCo has not read Portugal's own cancer registry, its survival figures or its stage at diagnosis.
No payer detail: who pays for cancer care in Portugal, what a patient pays, and which medicines are reimbursed.
No regulator detail: the national medicines agency's own procedures, beyond EU centralised authorisations.
No national cancer plan, guideline, screening schedule or treatment-centre list read from Portugal's own sources, beyond the programme records above.

A deep dive for Portugal is ranked 27 of 60 in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.

Sources and machine-readable data

IARC Global Cancer Observatory, GLOBOCAN 2024: Cancer Today; Portugal fact sheet.
ClinicalTrials.gov study records, courtesy of the US National Library of Medicine, as captured in each trial record.
OnCo records: each chip and card opens a record with its own sources.
This page as JSON: /api/v1/countries/pt.json; every country: /api/v1/countries.json.